Potential Role of Sirtuins As Epigenetic Biomarkers of the Patient with Atherosclerosis or Calcific Aortic Stenosis

Recruiting

• Conditions: Atherosclerosis and Calcific Aortic Stenosis with and Without Diabetes
• Interventions: Diagnostic Test: lncRNA signature analyses

• Registration Number: NCT06337227
• Lead Sponsor: IRCCS SYNLAB SDN

Brief Summary

The project aims to shed light on the role of Sirtuins, enzymes belonging to the third class of histone deacetylases (class III) involved in epigenetic modifications (deacetylation), focusing mainly on Sirtuin 6 (SIRT6), as a regulator of atherosclerosis and severe aortic valve stenosis through molecular-based and epigenetic studies in human VSMC cells.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-10-19
• Study First Submitted: 2024-03-22
• Study First Submitted QC: 2024-03-22
• Study First Posted: 2024-03-29
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-07
• Last Update Posted: 2025-03-11
• Primary Completion: 2025-10
• Study Completion: 2026-10

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

• Patients with atherosclerosis or calcific aortic stenosis with and without diabetes older than 18 years of either sex;
• Patients without atherosclerosis undergoing surgical procedure for endocarditis;
• Patients who will have signed informed consent

Exclusion Criteria

• Patients for whom biological material cannot be recovered for study purposes;
• Patients who refuse to participate in the study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
atherosclerosis and calcific aortic stenosis without diabetes patients	lncRNA signature analyses	-
atherosclerosis and calcific aortic stenosis with diabetes patients	lncRNA signature analyses	-
Patients without atherosclerosis undergoing surgical procedure for endocarditis	lncRNA signature analyses	-

Primary Outcome Measures

Name	Time	Method
To evaluate by analysis of data obtained from NGS techniques whether and which proteins belonging to the Sirtuin family may be deregulated in patients with atherosclerosis or calcific aortic stenosis	36 months

Secondary Outcome Measures

Name	Time	Method
To evaluate the experimental results achieved in the clinical-diagnostic context	36 months

Trial Locations

Locations (1)

Irccs Synlab Sdn; 🇮🇹 Naples, Italy